Cambridge Investment Research Advisors Inc. bought a new position in NeuroOne Medical Technologies Corporation (NASDAQ:NMTC – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 81,000 shares of the company’s stock, valued at approximately $69,000. Cambridge Investment Research Advisors Inc. owned 0.17% of NeuroOne Medical Technologies as of its most recent filing with the SEC.
Separately, Geode Capital Management LLC boosted its holdings in NeuroOne Medical Technologies by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 311,659 shares of the company’s stock worth $257,000 after buying an additional 27,804 shares during the period. Institutional investors and hedge funds own 16.07% of the company’s stock.
Analyst Ratings Changes
Separately, LADENBURG THALM/SH SH began coverage on shares of NeuroOne Medical Technologies in a report on Monday, May 5th. They set a “buy” rating and a $1.45 price objective for the company.
NeuroOne Medical Technologies Stock Down 2.8%
NMTC opened at $0.71 on Wednesday. The firm has a 50-day simple moving average of $0.65 and a two-hundred day simple moving average of $0.82. NeuroOne Medical Technologies Corporation has a 52 week low of $0.40 and a 52 week high of $1.39. The company has a market capitalization of $35.12 million, a PE ratio of -3.20 and a beta of 0.66.
NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. NeuroOne Medical Technologies had a negative net margin of 75.41% and a negative return on equity of 334.64%. The business had revenue of $1.39 billion during the quarter, compared to the consensus estimate of $1.27 billion.
NeuroOne Medical Technologies Company Profile
NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.
See Also
- Five stocks we like better than NeuroOne Medical Technologies
- There Are Different Types of Stock To Invest In
- JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth
- The 3 Best Fintech Stocks to Buy Now
- Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
- What is the Dow Jones Industrial Average (DJIA)?
- Fastenal Surges After Earnings Beat, Tariff Risks Loom
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
